Brownwood honors 911 dispatchers during National Public Safety Telecommunicators Week
ABILENE, Texas () – National Public Safety Telecommunicators Week, April 14-18, honors dispatchers who assess a situation and dispatch emergency services and law enforcement.
When the phone rings, someone is prepared to answer and assess calls for help. Brownwood 911 Dispatcher and shift supervisor Justin Storch stated that the job requires various skills.
'We're gathering information, ensuring public safety, officer safety, and then protection of property,' Storch said. 'As soon as we get a call, we have to decide what kind of call it is, and in seconds, get it on the board and get it out to an officer so they can respond as quick as possible.'
Dispatchers navigate chaos, occasionally having to deliver babies and provide CPR over the phone. Abilene Communications Manager, Lindsey Hoxsey, mentioned that this can be challenging.
'The harder ones are going to be CPR and stuff that deals with infants that don't come out great. You know, whenever somebody wakes up next to somebody that's passed away overnight, that they've been with for 60 years, those are pretty rough for us,' Hoxsey said.
As the job gains more public attention, Storch stated that discussing its mental health impact is increasingly important.
'We get them to the EMTs and firefighters to them and after that, we don't hear anything else. It can become emotionally difficult. It can weigh on a dispatcher quite a bit. One of the best things that we can do is have a good, strong support system, which we do from our officers, from our fellow dispatchers, and our families,' Storch explained.
Brownwood Lieutenant Art Sanders said it would be unimaginable in a world without dispatchers.
'It would be chaos. We wouldn't know where we're going. We wouldn't have— it would be up to us to find things going on all the time. And we just can't do that. You know, there's only a limited number of officers out there prowling around the streets,' said Sanders. 'They are the guys that are absolutely there all the time,' Sanders said.
Hoxsey said no matter the county, the overall vision is the same: to save lives and get people the help they need.
'Your worst day is our work day, and we want everybody to feel heard. And when they call, we want to make sure everybody feels like a priority. So we are here,' Hoxsey said.
In 2019, the state of Texas recognized dispatchers as first responders, allowing 911 operators to access the same benefits as law enforcement and emergency services.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Epoch Times
2 hours ago
- Epoch Times
Nasal, Baby Teething Swabs Recalled Nationwide Over Microbial Contamination Fears
New Jersey-based Church & Dwight Co., Inc. is recalling three nasal and baby teething swab products due to potential fungal contamination in the cotton swab components, the company said in a June 6 The recall is applicable to three products: Zicam Cold Remedy Nasal Swabs designed to tackle the common cold, Zicam Nasal AllClear Swabs used for cleansing, and Orajel Baby Teething Swabs aimed at soothing teething discomfort among toddlers and infants.
Yahoo
8 hours ago
- Yahoo
Why Oscar Health, Inc. (OSCR) Soared On Thursday
We recently published a list of . In this article, we are going to take a look at where Oscar Health, Inc. (NYSE:OSCR) stands against other best-performing stocks on Thursday. Oscar Health snapped a five-day losing streak on Thursday, jumping 10.6 percent to close at $15.65 apiece as investors resorted to bargain-hunting while waiting for more concrete developments on the Trump administration's Medicare Advantage review. Earlier this year, lawmakers passed a $5-trillion tax-and-spending package that shaves as much as $900 billion in Medicaid, which servers over 70 million low-income households. A close up of a patient and a healthcare professional engaging in conversation, showing the company's commitment to patient care. Now, Senate Republicans to broaden savings by looking for supposed inefficiencies in the Medicare program for senior citizens. In the first quarter of the year, Oscar Health, Inc. (NYSE:OSCR) registered a 55-percent increase in attributable net income of $275 million versus the $177 million registered in the same period last year. Revenues rose by 42 percent to $3.046 billion from $2.142 billion year-on-year. Overall, OSCR ranks 5th on our list of best-performing stocks on Thursday. While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 hours ago
- Yahoo
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic rating due to the company's VAFSEO product and its potential in the CKD anemia market. VAFSEO is an approved treatment for anemia in adults with chronic kidney disease on dialysis. According to the analyst, the treatment is gaining considerable momentum among dialysis organizations, and this trend is anticipated to support near-term growth. He expects VAFSEO's ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst also reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) is positioned for success as it has secured contracts that cover almost all dialysis patients in the US. VAFSEO offers flexibility in its dosing regimen, ranging from 150mg to 600mg, making it a factor that allows for personalized treatment and potentially growing prescriptions. Caufield pointed out VAFSEO's oral administration as another reason supporting the optimistic rating, giving it an advantage over existing therapies, such as iron supplementation and erythropoiesis-stimulating agents. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes drugs to treat metabolic and renal diseases. While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio